이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Toleranzia 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Charlotte Fribert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	8.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	6.5yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

CEO

Charlotte Fribert (57 yo)

8.3yrs

테뉴어

Ms. Charlotte Fribert has been the Chief Executive Officer of Toleranzia AB since April 15, 2016 and serves as Executive Director. Ms. Fribert served as Chief Operating Officer of Toleranzia AB until April...

리더십 팀

이름	위치	테뉴어	보상	소유권
Charlotte Fribert	CEO & Executive Director	8.3yrs	데이터 없음	데이터 없음
Thomas Palsson	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Björn Löwenadler	Chief Business Officer	6.5yrs	데이터 없음	데이터 없음
Vidar Wendel-Hansen	Chief Medical Officer	6.5yrs	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

68.5yo

평균 연령

경험이 풍부한 관리: TOL 의 관리팀은 노련하고 경험 (평균 재직 기간 6.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Charlotte Fribert	CEO & Executive Director	no data	데이터 없음	데이터 없음
Thomas Eldered	Director	2.8yrs	데이터 없음	27.01% SEK 33.9m
Jan Mattsson	Director	4.5yrs	데이터 없음	데이터 없음
Eva Lindgren	Director	6.5yrs	데이터 없음	데이터 없음
Maarten Kraan	Director	6.5yrs	데이터 없음	데이터 없음
Kristian Sandberg	Director	7.5yrs	데이터 없음	데이터 없음
Ann-Charlotte Rosendahl	Chair of the Board	4.5yrs	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: TOL 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Toleranzia 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Director recently bought kr462k worth of stock

Toleranzia AB, Annual General Meeting, Jun 19, 2024

Toleranzia AB Announces Executive Changes

Toleranzia AB Announces Appointment of Nomination Committee

No independent directors

Toleranzia Appoints Torbjörn Sannerstedt as New Chief Financial Officer

Recent updates

First quarter 2024 earnings released

Director recently bought kr462k worth of stock

Full year 2023 earnings released: kr0.038 loss per share (vs kr0.077 loss in FY 2022)

Toleranzia AB to Report Q2, 2024 Results on Aug 23, 2024

Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2

Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies

Toleranzia AB, Annual General Meeting, Jun 19, 2024

Third quarter 2023 earnings released

Toleranzia AB Announces Executive Changes

Toleranzia AB (publ) Starts Toxicology Study of its Lead Drug Candidate TOL2

New major risk - Shareholder dilution

Second quarter 2023 earnings released

Toleranzia AB (publ) Establishes a Freeze-Dried Formulation of the TOL2 Drug Product

Toleranzia AB (Publ) Run GMP Manufacturing of Drug Candidate Tol2 for Clinical Study

New minor risk - Share price stability

Full year 2022 earnings released: kr0.077 loss per share (vs kr0.089 loss in FY 2021)

Full year 2022 earnings released: kr0.077 loss per share (vs kr0.089 loss in FY 2021)

Toleranzia AB Announces Appointment of Nomination Committee

Toleranzia AB to Report Fiscal Year 2023 Results on Feb 23, 2024

Toleranzia AB (Publ) Announces Successful Large-Scale Production of Drug Candidate TOL2

No independent directors

Third quarter 2022 earnings released

Second quarter 2022 earnings released

Toleranzia Appoints Torbjörn Sannerstedt as New Chief Financial Officer

Toleranzia AB (publ) Announces Positive Results for Toleranzia's Drug Candidate ToL2 Published in Reputable Scientific Journal

Toleranzia AB to Report Fiscal Year 2022 Results on Feb 24, 2023

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Toleranzia Announces Continued Promising Results in the Production of TOL2

Full year 2020 earnings released: kr0.09 loss per share (vs kr0.47 loss in FY 2019)

New 90-day low: kr1.33

New 90-day high: kr1.54

New 90-day low: kr1.49

New 90-day low - kr1.67

First half earnings released

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령